Edwards Lifesciences EPS - Earnings per Share 2010-2025 | EW
Edwards Lifesciences annual and quarterly earnings per share history from 2010 to 2025. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- Edwards Lifesciences EPS for the quarter ending March 31, 2025 was $0.61, a 5.17% increase year-over-year.
- Edwards Lifesciences EPS for the twelve months ending March 31, 2025 was $7.00, a 201.72% increase year-over-year.
- Edwards Lifesciences 2024 annual EPS was $6.97, a 203.04% increase from 2023.
- Edwards Lifesciences 2023 annual EPS was $2.3, a 5.74% decline from 2022.
- Edwards Lifesciences 2022 annual EPS was $2.44, a 2.52% increase from 2021.
| Edwards Lifesciences Annual EPS |
| 2024 |
$6.97 |
| 2023 |
$2.30 |
| 2022 |
$2.44 |
| 2021 |
$2.38 |
| 2020 |
$1.30 |
| 2019 |
$1.64 |
| 2018 |
$1.13 |
| 2017 |
$0.90 |
| 2016 |
$0.87 |
| 2015 |
$0.75 |
| 2014 |
$1.25 |
| 2013 |
$0.57 |
| 2012 |
$0.41 |
| 2011 |
$0.33 |
| 2010 |
$0.31 |
| 2009 |
$0.33 |
| Edwards Lifesciences Quarterly EPS |
| 2025-03-31 |
$0.61 |
| 2024-12-31 |
$0.65 |
| 2024-09-30 |
$5.13 |
| 2024-06-30 |
$0.61 |
| 2024-03-31 |
$0.58 |
| 2023-12-31 |
$0.61 |
| 2023-09-30 |
$0.63 |
| 2023-06-30 |
$0.50 |
| 2023-03-31 |
$0.56 |
| 2022-12-31 |
$0.65 |
| 2022-09-30 |
$0.55 |
| 2022-06-30 |
$0.65 |
| 2022-03-31 |
$0.59 |
| 2021-12-31 |
$0.52 |
| 2021-09-30 |
$0.54 |
| 2021-06-30 |
$0.78 |
| 2021-03-31 |
$0.54 |
| 2020-12-31 |
$0.49 |
| 2020-09-30 |
$0.52 |
| 2020-06-30 |
$-0.20 |
| 2020-03-31 |
$0.49 |
| 2019-12-31 |
$0.44 |
| 2019-09-30 |
$0.43 |
| 2019-06-30 |
$0.38 |
| 2019-03-31 |
$0.39 |
| 2018-12-31 |
$0.02 |
| 2018-09-30 |
$0.35 |
| 2018-06-30 |
$0.44 |
| 2018-03-31 |
$0.32 |
| 2017-12-31 |
$0.00 |
| 2017-09-30 |
$0.26 |
| 2017-06-30 |
$0.29 |
| 2017-03-31 |
$0.35 |
| 2016-12-31 |
$0.24 |
| 2016-09-30 |
$0.22 |
| 2016-06-30 |
$0.19 |
| 2016-03-31 |
$0.22 |
| 2015-12-31 |
$0.21 |
| 2015-09-30 |
$0.18 |
| 2015-06-30 |
$0.17 |
| 2015-03-31 |
$0.19 |
| 2014-12-31 |
$0.16 |
| 2014-09-30 |
$0.15 |
| 2014-06-30 |
$0.85 |
| 2014-03-31 |
$0.09 |
| 2013-12-31 |
$0.12 |
| 2013-09-30 |
$0.11 |
| 2013-06-30 |
$0.14 |
| 2013-03-31 |
$0.21 |
| 2012-12-31 |
$0.13 |
| 2012-09-30 |
$0.10 |
| 2012-06-30 |
$0.10 |
| 2012-03-31 |
$0.09 |
| 2011-12-31 |
$0.09 |
| 2011-09-30 |
$0.07 |
| 2011-06-30 |
$0.08 |
| 2011-03-31 |
$0.09 |
| 2010-12-31 |
$0.09 |
| 2010-09-30 |
$0.07 |
| 2010-06-30 |
$0.08 |
| 2010-03-31 |
$0.07 |
| 2009-12-31 |
$0.07 |
| 2009-09-30 |
$0.11 |
| 2009-06-30 |
$0.07 |
| 2009-03-31 |
$0.09 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED INSTRUMENTS |
$44.196B |
$5.440B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
